These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 23800326)

  • 21. Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study.
    Nichols BE; Boucher CA; van Dijk JH; Thuma PE; Nouwen JL; Baltussen R; van de Wijgert J; Sloot PM; van de Vijver DA
    PLoS One; 2013; 8(3):e59549. PubMed ID: 23527217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-exposure prophylaxis (PrEP) in HIV-uninfected individuals with high-risk behaviour.
    Nadery S; Geerlings SE
    Neth J Med; 2013; 71(6):295-9. PubMed ID: 23956310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis.
    Baeten J; Celum C
    Annu Rev Med; 2013; 64():219-32. PubMed ID: 23020883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.
    Haire B; Folayan MO; Hankins C; Sugarman J; McCormack S; Ramjee G; Warren M
    Dev World Bioeth; 2013 Aug; 13(2):87-94. PubMed ID: 23725227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
    Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN
    Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
    Haberer JE
    Curr Opin HIV AIDS; 2016 Jan; 11(1):10-7. PubMed ID: 26633638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attitudes Towards PrEP and Anticipated Condom Use Among Concordant HIV-Negative and HIV-Discordant Male Couples.
    Hoff CC; Chakravarty D; Bircher AE; Campbell CK; Grisham K; Neilands TB; Wilson PA; Dworkin S
    AIDS Patient Care STDS; 2015 Jul; 29(7):408-17. PubMed ID: 26057304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges.
    Kesho Bora Study Group
    Contemp Clin Trials; 2011 Jan; 32(1):74-85. PubMed ID: 20854932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Motivations for pre-exposure prophylaxis uptake and decline in an HIV-hyperendemic setting: findings from a qualitative implementation study in Lesotho.
    Chebet JJ; McMahon SA; Tarumbiswa T; Hlalele H; Maponga C; Mandara E; Ernst K; Alaofe H; Baernighausen T; Ehiri JE; Geldsetzer P; Nichter M
    AIDS Res Ther; 2023 Jul; 20(1):43. PubMed ID: 37415180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventing HIV among adolescents with oral PrEP: observations and challenges in the United States and South Africa.
    Hosek S; Celum C; Wilson CM; Kapogiannis B; Delany-Moretlwe S; Bekker LG
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21107. PubMed ID: 27760684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emtricitabine + tenofovir to prevent HIV transmission. More evaluation needed.
    Prescrire Int; 2013 Jul; 22(140):178-81. PubMed ID: 23951592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
    Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
    Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons.
    Pattacini L; Murnane PM; Baeten JM; Fluharty TR; Thomas KK; Bukusi E; Katabira E; Mugo N; Donnell D; Lingappa JR; Celum C; Marzinke M; McElrath MJ; Lund JM;
    J Infect Dis; 2015 Jun; 211(12):1943-52. PubMed ID: 25520426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USA.
    Elion R; Coleman M
    Curr Opin HIV AIDS; 2016 Jan; 11(1):67-73. PubMed ID: 26599165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
    Mugwanya KK; Baeten JM
    Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Promise and pitfalls of pre-exposure prophylaxis for female sex workers.
    Cowan FM; Delany-Moretlwe S
    Curr Opin HIV AIDS; 2016 Jan; 11(1):27-34. PubMed ID: 26633639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lay Social Resources for Support of Adherence to Antiretroviral Prophylaxis for HIV Prevention Among Serodiscordant Couples in sub-Saharan Africa: A Qualitative Study.
    Ware NC; Pisarski EE; Haberer JE; Wyatt MA; Tumwesigye E; Baeten JM; Celum CL; Bangsberg DR
    AIDS Behav; 2015 May; 19(5):811-20. PubMed ID: 25267114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preexposure prophylaxis for the prevention of HIV transmission to women.
    Aaron E; Cohan D
    AIDS; 2013 Jan; 27(1):F1-5. PubMed ID: 22914582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of pre-exposure prophylaxis for HIV: a review.
    Schackman BR; Eggman AA
    Curr Opin HIV AIDS; 2012 Nov; 7(6):587-92. PubMed ID: 23076124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.